Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00425373
Status:
COMPLETED
Last Update Posted:
2011-04-29
First Post:
2007-01-22
Brief Title:
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Multi-center Randomized Double-blind Parallel-group Placebo-controlled Factorial Study to Evaluate the Efficacy and Safety of 8-week Treatment With Valsartan 40 and 80 mg and Amlodipine 25 and 5 mg Combined and Alone in Essential Hypertensive Patients
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of fixed combination of valsartan 40 mg and 80 mg and amlodipine 25 mg and 5 mg valsartan and amlodipine alone and placebo in reducing blood pressure The study will investigate the dose response relationship for the combinations monotherapies and placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None